



MEET WITH AN ONCOLOGY THOUGHT LEADER

SCHEDULE ▶ MEET ▶ LEARN ▶ ENGAGE

The NERLYNX mChat™ program invites you to hear from a HER2+ breast cancer thought leader for a 30-minute virtual presentation on the clinical benefits and safety profile of NERLYNX. Through the mChat™ website, you can schedule a presentation with a regional thought leader to cover one of the following topics:

1 NERLYNX: Final iDFS and OS Results From ExteNET

2 Proactive Management Strategies With NERLYNX in HER2+ eBC

3 Clinic in Focus: HER2+ HR+ eBC Patient Cases

Sessions include Q&A time to discuss your specific clinical interests.

SIGN UP TODAY
Scan the code or visit
mChatForNERLYNX.com



eBC: early-stage breast cancer; HR+: hormone-receptor positive; iDFS: invasive disease-free survival; OS: overall survival.

INDICATION: NERLYNX® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:

- As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.

Please see IMPORTANT SAFETY INFORMATION on back and accompanying [Full Prescribing Information](#).

nerlynx®
(neratinib) tablets

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

- **Diarrhea:** Manage diarrhea through either NERLYNX dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction.
- **Hepatotoxicity:** Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.
- **Embryo-Fetal Toxicity:** NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common adverse reactions (reported in $\geq 5\%$ of patients) were:

- NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

- Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate NERLYNX by at least 2 hours before or 10 hours after H₂-receptor antagonists. Or separate NERLYNX by at least 3 hours after antacids.
- Strong CYP3A4 inhibitors: Avoid concomitant use.
- P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use.
- Strong or moderate CYP3A4 inducers: Avoid concomitant use.
- Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with NERLYNX.

USE IN SPECIFIC POPULATIONS:

- **Lactation:** Advise women not to breastfeed.

Please see accompanying [Full Prescribing Information](#).